Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors

Bischoff, Mark; Bischoff, G.; Buck, Andreas K.; Baer, Alexandra von; Pauls, Sandra; Scheffold, Florian; Schultheiß, Markus; Gebhard, Florian; Reske, Sven N.

doi:10.1007/s00402-009-0937-2

Cited by 17 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recently FDG-PET/CT analysis has been re-examined and its efficiency was investigated (20). Bischoff et al (21) reported that the usefulness of FDG-PET/CT in soft tissue and osseous tumors had a sensitivity of 69–80%, a specificity of 83–100% and an accuracy of 79–86%; although their criteria for interpreting malignant tumors were obscure and required the judgment of radiologists from numerous sources of information for conventional imaging. Charest et al (20) demonstrated a high sensitivity for the accurate discrimination between low- and high-grade sarcomas, however, not between benign and malignant soft tissue tumors.…”

Section: Discussionmentioning

confidence: 99%

Role of FDG-PET/CT for monitoring soft tissue tumors

et al. 2014

View full text Add to dashboard Cite

The aim of the current study was to evaluate the limitations of 2-deoxy-2-F18-fluoro-D-glucose positron emission tomography combined with computed tomography (FDG-PET/CT) when monitoring soft tissue tumors. The diagnostic criteria of malignancy was defined as the tumor having a maximum standardized uptake value (SUVmax) ≥2.0 and a maximum diameter ≥5 cm as measured using FDG-PET/CT. One-hundred-and-thirteen patients, that were either included in the criteria or not, were compared. In addition, the values of SUVmax of the primary tumor and relapse in 12 patients were evaluated. The Kaplan-Meier analysis demonstrated that patients with tumors measuring ≥5 cm size and ≥2.0 SUVmax were associated with a worse survival rate. Among the 12 patients with relapse, statistical significances were detected in the tumor diameters, however, not in the SUVmax values. Thus, the criteria identified patients that were associated with a poor prognosis, and the SUVmax of distant metastases and local recurrences were identified to be significantly affected by tumor size.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of FDG-PET/CT for monitoring soft tissue tumors

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[37] Furthermore, 18 F-FDG PET-CT has been shown to better differentiate soft-tissue and osseous malignancies from benign lesions compared to PET or CT alone. [38][39][40][41] In addition to 18 F-FDG, several novel PET radiotracers have shown promising results. 18 F-Fluoroestradiol, which targets estrogen receptors (ER) has been shown to have a high sensitivity for the detection of ER-positive skeletal metastases and is useful for quantifying in vivo ER expression without the need for biopsy.…”

Section: Figure 1: From Omics To Molecular Imaging and Precision Medi...mentioning

confidence: 99%

Advanced modalities of molecular imaging in precision medicine for musculoskeletal malignancies

et al. 2019

View full text Add to dashboard Cite

Musculoskeletal malignancies consist of a heterogenous group of mesenchymal tumors, often with high inter- and intratumoral heterogeneity. The early and accurate diagnosis of these malignancies can have a substantial impact on optimal treatment and quality of life for these patients. Several new applications and techniques have emerged in molecular imaging, including advances in multimodality imaging, the development of novel radiotracers, and advances in image analysis with radiomics and artificial intelligence. This review highlights the recent advances in molecular imaging modalities and the role of non-invasive imaging in evaluating tumor biology in the era of precision medicine.

show abstract

“…Morphological imaging modalities, specifically CT and MRI, are known to have limitations in differential diagnosis, and FDG PET/CT using tumor lesion SUV has been reported to better guide differential diagnosis [129,130]. However, a certain amount of overlap in FDG uptake exists between malignant and benign tumors and between low-grade and high-grade sarcomas [129][130][131][132].…”

Section: Sarcomamentioning

confidence: 99%

Radiomics in Oncological PET/CT: Clinical Applications

Lee

2017

Nucl Med Mol Imaging

View full text Add to dashboard Cite

F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely used for staging, evaluating treatment response, and predicting prognosis in malignant diseases. FDG uptake and volumetric PET parameters such as metabolic tumor volume have been used and are still used as conventional PET parameters to assess biological characteristics of tumors. However, in recent years, additional features derived from PET images by computational processing have been found to reflect intratumoral heterogeneity, which is related to biological tumor features, and to provide additional predictive and prognostic information, which leads to the concept of radiomics. In this review, we focus on recent clinical studies of malignant diseases that investigated intratumoral heterogeneity on PET/CT, and we discuss its clinical role in various cancers.

show abstract

Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors

Abstract: Combined FDG-PET-CT reliably differentiates soft tissue and bone tumors from benign lesions. The value of the information provided by FDG-PET-CT for planning surgical procedures must be evaluated in further studies.

Cited by 17 publications

References 29 publications

Role of FDG-PET/CT for monitoring soft tissue tumors

Role of FDG-PET/CT for monitoring soft tissue tumors

Advanced modalities of molecular imaging in precision medicine for musculoskeletal malignancies

Radiomics in Oncological PET/CT: Clinical Applications

Contact Info

Product

Resources

About